1.
Clin Pharmacol Ther
; 99(4): 360-2, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26765222
RESUMO
Therapies that modulate cyclic guanosine-3'-5'-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.